Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Alimera Sciences Inc. (ALIM)

4.86   -0.43 (-8.13%) 10-01 08:43
Open: 5 Pre. Close: 5.29
High: 5.065 Low: 4.85
Volume: 23,126 Market Cap: 24M
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. The company is headquartered in Alpharetta, Georgia and currently employs 124 full-time employees. The firm is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The firm operates through U.S. and International segment. The firm focuses on diseases affecting the back of the eye or retina. The firm's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, Canada, Lebanon and the United Arab Emirates, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.076 - 5.103 5.103 - 5.125
Low: 4.788 - 4.818 4.818 - 4.843
Close: 4.812 - 4.862 4.862 - 4.904

Technical analysis

as of: 2020-09-30 4:38:29 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 6.77     One year: 7.48
Support: Support1: 4.82    Support2: 4.01
Resistance: Resistance1: 5.80    Resistance2: 6.40
Pivot: 5.36
Moving Average: MA(5): 5.05     MA(20): 5.43
MA(100): 5.75     MA(250): 5.34
MACD: MACD(12,26): -0.26     Signal(9): -0.22
Stochastic oscillator: %K(14,3): 21.30     %D(3): 23.87
RSI: RSI(14): 31.91
52-week: High: 9.98  Low:   Change(%): 1004.5
Average Vol(K): 3-Month: 4709  10-Days: 1246

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
ALIM has closed above bottom band by 5.7%. Bollinger Bands are 17.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 23 Sep 2020
Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual Congress - Yahoo Finance

Tue, 15 Sep 2020
Alimera Sciences (ALIM) Announces Distribution Agreement with Medis Pharmaceutical to Commercialize Iluvien in Austria and the Czech Republic - StreetInsider.com

Tue, 15 Sep 2020
Need To Know: Alimera Sciences, Inc. (NASDAQ:ALIM) Insiders Have Been Selling Shares - Simply Wall St

Wed, 09 Sep 2020
Alimera Sciences Announces Participation at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 15, 2020 - GlobeNewswire

Tue, 08 Sep 2020
Alimera Sciences Obtains Reimbursement Approval for ILUVIEN® Use in Non-Infectious Posterior Uveitis in Scotland - GlobeNewswire

Wed, 26 Aug 2020
Alimera Sciences Announces National Reimbursement Granted for ILUVIEN® in the Netherlands - GlobeNewswire

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Underperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Outperform Debt to Equity: Underperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers General Specialty & Generic
Shares Out. (M) 5
Shares Float (M) 3
% Held by Insiders 17.95
% Held by Institutions 49.06
Shares Short (K) 34
Shares Short P. Month (K) 23

Stock Financials

EPS -1.300
EPS Est This Year -0.210
EPS Est Next Year -0.080
Book Value (p.s.) -7.530
Profit Margin -11.66
Operating Margin -2.81
Return on Assets (ttm) -1.9
Return on Equity (ttm)
Qtrly Rev. Growth -7.5
Gross Profit (p.s.) 9.408
Sales Per Share 10.889
EBITDA (p.s.) 0.225
Qtrly Earnings Growth
Operating Cash Flow (M) -3
Levered Free Cash Flow (M) -2

Stock Valuations

PE Ratio -3.74
PEG Ratio
Price to Book value -0.65
Price to Sales 0.45
Price to Cash Flow -7.50

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.